The antiangiogenic activity of a soluble fragment of the VEGFR extracellular domain

Biomedicine and Pharmacotherapy

Volumn 67, Issue 7, 2013, Pages 599-606

  Li, Haixin ^a   Cao, Wanlu ^a   Chen, Zhiguo ^a   Acheampong, Desmond Omane ^a   Jin, Haizhen ^a   Li, Daojuan ^a   Zhang, Juan ^a   Wang, Min ^a  

^a China Pharmaceutical University   (China)

Author keywords

Antiangiogenic activity; Periplasmic expression; VEGFR 2

Indexed keywords

SUNITINIB; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANION EXCHANGE CHROMATOGRAPHY; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASSAY; CANCER DIAGNOSIS; CANCER RESEARCH; CANCER THERAPY; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; DISSOCIATION; DISSOCIATION CONSTANT; ENDOTHELIUM CELL; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; KINETICS; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE;

ANTIANGIOGENIC ACTIVITY; BOVINE SERUM ALBUM; BSA; CAM; CHORIOALLANTOIC MEMBRANE; DISSOCIATION; E. COLI; EC; EGF; ELISA; ENDOTHELIAL CELLS; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; EQUILIBRIUM CONSTANT; ESCHERICHIA COLI; FBS; FETAL BOVINE SERUM; FGF; FIBROBLAST GROWTH FACTORS; IFN-Γ; INTERFERON-Γ; K(A); K(D); KD; KDR; KINASE-INSERT DOMAIN-CONTAINING RECEPTOR (AS IT IS CALLED IN HUMAN); MAB; MONOCLONAL ANTIBODY; PERIPLASMIC EXPRESSION; SPR; SURFACE PLASMON RESONANCE; THE KINETIC CONSTANT FOR ASSOCIATION; TNF-Α; TUMOR NECROSIS FACTOR-Α; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF; VEGF RECEPTOR-2; VEGFR-2; VEGFR2;

ANGIOGENESIS INHIBITORS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHORIOALLANTOIC MEMBRANE; ENDOTHELIUM, VASCULAR; HUMANS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; SOLUBILITY; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84884816444     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.06.001     Document Type: Article

References (31)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186.
2. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997, 18(1):4-25.
3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6(4):389-395.
4. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9(6):669-676.
5. Ferrara N., Gerber H.P. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001, 106(4):148-156.
6. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23(5):1011-1027.
7. Terman B.I., Carrion M.E., Kovacs E., et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991, 6(9):1677-1683.
8. Shinkai A., Ito M., Anazawa H., et al. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem 1998, 273(47):31283-31288.
9. Fuh G., Li B., Crowley C., et al. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem 1998, 273(18):11197-11204.
10. Waltenberger J., Claesson-Welsh L., Siegbahn A., et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994, 269(43):26988-26995.
11. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001, 7(5):575-583.
12. Ferrara N., Chen H., Davis-Smyth T., et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998, 4(3):336-340.
13. Gerber H.P., Vu T.H., Ryan A.M., et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999, 5(6):623-628.
14. Kuo C.J., Farnebo F., Yu E.Y., et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci U S A 2001, 98(8):4605-4610.
15. Papadopoulos N., Martin J., Ruan Q., et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis 2012, 15(2):171-185.
16. Ben-Yosef Y., Lahat N., Shapiro S., et al. Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res 2002, 90(7):784-791.
17. Oberleithner H., Riethmüller C., Schillers H., MacGregor G.A., et al. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci U S A 2007, 104(41):16281-16286.
18. Malik A., Jenzsch M., Lübbert A., et al. Periplasmic production of native human proinsulin as a fusion to E. coli ecotin. Protein Expr Purif 2007, 55(1):100-111.
19. Liu Z., Gurlo T., von Grafenstein H. Cell-ELISA using beta-galactosidase conjugated antibodies. J Immunol Methods 2000, 234(1-2):153-167.
20. Yujuan Shan, Lanwei Zhang, Yongping Bao, et al. Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. J Nutr Biochem 2012.
21. Hoeben A., Landuyt B., Highley M.S., et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004, 56(4):549-580.
22. Takayama Y., Akutsu H. Expression in periplasmic space of Shewanella oneidensis. Protein Expr Purif 2007, 56(1):80-84.
23. Li X., Xu T., Ma X., et al. Optimization of culture conditions for production of cis-epoxysuccinic acid hydrolase using response surface methodology. Bioresour Technol 2008, 99(13):5391-5396.
24. Zhang J., Li H., Chen W., et al. Preparation of extracellular domain 3 of human VEGF receptor-2 and the monitoring of its real-time binding to VEGF by biosensors. Biotechnol Prog 2009, 25(6):1703-1708.
25. Ribatti D., Vacca A. Models for studying angiogenesis in vivo. Int J Biol Markers 1999, 14(4):207-213.
26. Bootle-Wilbraham C.A., Tazzyman S., Thompson W.D., et al. Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro. Angiogenesis 2001, 4(4):269-275.
27. Folkman J. Proceedings: tumor angiogenesis factor. Cancer Res 1974, 34(8):2109-2113.
28. Thompson W.D., Campbell R., Evans T. Fibrin degradation and angiogenesis: quantitative analysis of the angiogenic response in the chick chorioallantoic membrane. J Pathol 1985, 145(1):27-37.
29. Li Y.J., Duan C.L., Liu J.X., et al. Pro-angiogenic actions of Salvianolic acids on in vitro cultured endothelial progenitor cells and chick embryo chorioallantoic membrane model. J Ethnopharmacol 2010, 131(3):562-566.
30. Ribatti D. Chick embryo chorioallantoic membrane as a useful tool to study angiogenesis. Int Rev Cell Mol Biol 2008, 270:181-224.
31. Eskens F.A., Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006, 42(18):3127-3139.